Drug Discovery, Pharmaceuticals & Cannabis Testing
New virus removal fi lter enhances biopharmaceutical effi ciency
Asahi Kasei Medical announced the launch of its Planova™ FG1, a next-generation virus removal filter designed for biopharmaceutical manufacturing. Released in October 2024, the Planova™ FG1 features significantly higher flux, enhancing the efficiency and safety of biotherapeutic production processes.
The bioprocess business of Asahi Kasei Medical focuses on providing Planova™ virus removal filters, equipment, biosafety testing services, and biopharmaceutical CDMO operations. Planova™ products, sold since 1989, have continuously evolved to meet the rising global demands for viral safety in biopharmaceuticals. The product lineup expanded with the introduction of Planova™ BioEX in 2009 and Planova™ S20N in 2022. With the addition of the Planova™ FG1, the company aims to further support the growing demand for monoclonal antibodies and biopharmaceuticals, which are projected to grow at 5-10% annually.
The Planova™ FG1 is engineered for optimal productivity in biopharmaceutical manufacturing, offering rapid filtration and robust virus removal capabilities. Its high flux rate - approximately seven times greater than that of Planova™ BioEX - enables faster filtration and minimises the risk of virus breakthrough during filtration suspension. Customer evaluations during development confirmed excellent protein filtration and virus removal performance, even without a prefilter for aggregates. Additionally, Planova™ FG1 is compatible with standard cleaning-in-place (CIP) and sterilisation-in-place (SIP) processes, ensuring it integrates smoothly with a wide range of existing manufacturing equipment.
Mass production and shipments of smaller Planova™ FG1 filters began in October 2024, with plans to expand the product range to include larger filters for process scaling. This new addition to the Planova™ lineup strengthens Asahi Kasei Medical’s commitment to enhancing the productivity, safety, and efficiency of pharmaceutical manufacturing.
“We are excited to introduce the Planova™ FG1 and to continue supporting the biopharmaceutical industry with our growing portfolio of innovative solutions,” said Ken Shinomiya, President of Asahi Kasei Medical. “Our products are designed to ensure the safe, efficient manufacturing of biopharmaceuticals that patients can trust.”
More information online:
ilmt.co/PL/x5lM 63794pr@reply-direct.com New website simplifi es access for biotech and biopharma users
ProBioGen has launched its redesigned website, offering biotech and biopharma professionals streamlined access to its expanded services and proprietary technologies. The updated platform delivers an intuitive user experience, enabling faster navigation and easier access to essential information.
The enhanced website provides a seamless way to explore ProBioGen’s comprehensive portfolio, which includes cell line development, cell banking, process and full analytical development, GMP manufacturing, and advanced solutions for proteins, viral vectors, and vaccines. It also highlights proprietary technologies like GlymaxX® and DirectedLuck®, designed to improve efficacy, boost productivity, and accelerate time to clinic.
With a clearer structure, the new website makes it easier than ever to find relevant content. Dedicated sections for CDMO services, technologies, news, resources, and company information ensure visitors can quickly access what they need. The site also features detailed descriptions of ProBioGen’s portfolio, along with scientific studies, white papers, and industry updates, providing comprehensive insights to help users make informed decisions and advance their projects.
Designed for convenience, the fully responsive and interactive interface allows seamless browsing across all devices. Whether on a desktop or mobile, users can efficiently navigate the platform and access key information anytime, anywhere.
“Our updated website reflects ProBioGen’s commitment to innovation and customer collaboration,” said Dr Gabriele Schneider, Chief Business Officer at ProBioGen. “By prioritising clarity and ease of use, we empower visitors to make informed decisions, streamline project planning, and accelerate progress in next-generation therapies.”
More information online:
ilmt.co/PL/89Qp 63917pr@reply-direct.com New assay kit transforms drug bioavailability testing
A new PhysioMimix® Bioavailability Assay Kit: Human 18 has been launched, offering researchers the ability to profile human oral drug bioavailability in vitro within their own laboratories. This innovative kit from CN Bio builds on advanced multi-organ Gut/Liver-on-a-chip technology, helping accelerate drug development by addressing limitations of traditional approaches and supporting safer, more effective clinical progression.
Accurately predicting bioavailability is a critical step in preclinical drug development, guiding safe dosage decisions in the clinic. Current methods, including in vitro assays, animal studies, and computational models, face challenges such as limited complexity in 2D cell cultures and poor translatability from animal data. The new assay kit provides a streamlined and predictive solution, enabling earlier and more accurate profiling of bioavailability to de-risk drug development pipelines.
Developed after the success of a similar assay offered through an ADME Contract Research Service earlier this year, the PhysioMimix Bioavailability Assay Kit: Human 18 has been optimised into a convenient format for independent use. It is designed for use with the PhysioMimix® Multi-organ System, integrating human-derived models of the gut and liver into a single system to simulate key processes of drug absorption, metabolism, and clearance. This dual-organ approach uniquely supports both oral and intravenous dosing, allowing researchers to evaluate candidates with precision.
The Gut/Liver-on-a-chip model combines Altis Biosystems’ RepliGut® Jejunum model with a highly characterised Liver-on-a-chip, developed in partnership with Altis Biosystems. The system fluidically links the two organs, accurately recapitulating processes such as intestinal metabolism and
hepatic clearance. By enabling up to 18 replicates, the kit provides researchers with robust data to guide candidate selection, improve study design, and minimise the use of animal models.
Dr Yassen Abbas, Lead Scientist, highlighted that the kit reduces the burden of assay development, enabling labs to quickly adopt advanced organ-on-a-chip technology. Dr Ben Scruggs, CEO of Altis Biosystems, emphasised the significance of making this powerful model accessible for in-house use, ensuring better predictive data and more efficient workflows. This new assay kit represents a step forward in modernising preclinical testing and improving the success rate of clinical drug candidates. More information online:
ilmt.co/PL/A7Xq
63655pr@reply-direct.com
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48
